These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 20606093)

  • 1. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
    Philip PA; Benedetti J; Corless CL; Wong R; O'Reilly EM; Flynn PJ; Rowland KM; Atkins JN; Mirtsching BC; Rivkin SE; Khorana AA; Goldman B; Fenoglio-Preiser CM; Abbruzzese JL; Blanke CD
    J Clin Oncol; 2010 Aug; 28(22):3605-10. PubMed ID: 20606093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer.
    Moinpour CM; Vaught NL; Goldman B; Redman MW; Philip PA; Millwood B; Lippman SM; Seay TE; Flynn PJ; O'Reilly EM; Rowland KM; Wong RP; Benedetti J; Blanke CD
    J Clin Oncol; 2010 Aug; 28(22):3611-6. PubMed ID: 20606094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
    Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
    Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
    Cascinu S; Berardi R; Labianca R; Siena S; Falcone A; Aitini E; Barni S; Di Costanzo F; Dapretto E; Tonini G; Pierantoni C; Artale S; Rota S; Floriani I; Scartozzi M; Zaniboni A;
    Lancet Oncol; 2008 Jan; 9(1):39-44. PubMed ID: 18077217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
    Ko AH; Youssoufian H; Gurtler J; Dicke K; Kayaleh O; Lenz HJ; Keaton M; Katz T; Ballal S; Rowinsky EK
    Invest New Drugs; 2012 Aug; 30(4):1597-606. PubMed ID: 21629990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
    Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
    Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer.
    Su D; Jiao SC; Wang LJ; Shi WW; Long YY; Li J; Bai L
    Tumour Biol; 2014 Mar; 35(3):2313-8. PubMed ID: 24142531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
    Xiong HQ; Rosenberg A; LoBuglio A; Schmidt W; Wolff RA; Deutsch J; Needle M; Abbruzzese JL
    J Clin Oncol; 2004 Jul; 22(13):2610-6. PubMed ID: 15226328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].
    Krempien R; Muenter MW; Huber PE; Nill S; Friess H; Timke C; Didinger B; Buechler P; Heeger S; Herfarth KK; Abdollahi A; Buchler MW; Debus J
    BMC Cancer; 2005 Oct; 5():131. PubMed ID: 16219105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
    Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
    Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer.
    Arnoletti JP; Frolov A; Eloubeidi M; Keene K; Posey J; Wood T; Greeno E; Jhala N; Varadarajulu S; Russo S; Christein J; Oster R; Buchsbaum DJ; Vickers SM
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):891-7. PubMed ID: 20589377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).
    Philip PA; Goldman B; Ramanathan RK; Lenz HJ; Lowy AM; Whitehead RP; Wakatsuki T; Iqbal S; Gaur R; Benedetti JK; Blanke CD
    Cancer; 2014 Oct; 120(19):2980-5. PubMed ID: 25041791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.
    Wolpin BM; O'Reilly EM; Ko YJ; Blaszkowsky LS; Rarick M; Rocha-Lima CM; Ritch P; Chan E; Spratlin J; Macarulla T; McWhirter E; Pezet D; Lichinitser M; Roman L; Hartford A; Morrison K; Jackson L; Vincent M; Reyno L; Hidalgo M
    Ann Oncol; 2013 Jul; 24(7):1792-1801. PubMed ID: 23448807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.
    Crane CH; Varadhachary GR; Yordy JS; Staerkel GA; Javle MM; Safran H; Haque W; Hobbs BD; Krishnan S; Fleming JB; Das P; Lee JE; Abbruzzese JL; Wolff RA
    J Clin Oncol; 2011 Aug; 29(22):3037-43. PubMed ID: 21709185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
    Moore MJ; Goldstein D; Hamm J; Figer A; Hecht JR; Gallinger S; Au HJ; Murawa P; Walde D; Wolff RA; Campos D; Lim R; Ding K; Clark G; Voskoglou-Nomikos T; Ptasynski M; Parulekar W;
    J Clin Oncol; 2007 May; 25(15):1960-6. PubMed ID: 17452677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
    Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
    J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
    Merchan JR; Ferrell A; Macintyre J; Ciombor KK; Levi J; Ribeiro A; Sleeman D; Flores A; Lopes G; Rocha-Lima CM
    Am J Clin Oncol; 2012 Oct; 35(5):446-50. PubMed ID: 21552097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
    Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M
    Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study.
    Kullmann F; Hollerbach S; Dollinger MM; Harder J; Fuchs M; Messmann H; Trojan J; Gäbele E; Hinke A; Hollerbach C; Endlicher E
    Br J Cancer; 2009 Apr; 100(7):1032-6. PubMed ID: 19293797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.
    Butts CA; Bodkin D; Middleman EL; Englund CW; Ellison D; Alam Y; Kreisman H; Graze P; Maher J; Ross HJ; Ellis PM; McNulty W; Kaplan E; Pautret V; Weber MR; Shepherd FA
    J Clin Oncol; 2007 Dec; 25(36):5777-84. PubMed ID: 18089875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.